Yt90 Zevalin [ibritumomab-tiuxetan-Y-90] and combination chemotherapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2015
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 29 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jan 2010 Planned end date changed from 1 Sep 2009 to 1 Mar 2012 as reported by ClinicalTrials.gov.